Seeking Alpha
07 May 2026, 16:50 UTC · 19w ago
Verdict
Headline takes no side. We score MNKD −0.60 — strongly bearish.
−0.60strongly bearish
More negative than 86% of ticker scores this week
Which stocks this story touches
More negative than 86% of ticker scores this week
The company faces margin pressure, reliance on niche assets, and competitive threats to its royalties.
More positive than 63% of ticker scores this week
The launch of Tresmi is positioned as a competitive threat to MannKind, suggesting market gain for United Therapeutics.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Search tags
More positive than 58% of relationship scores this week
[mutual] United Therapeutics' launch of Tresmi competes with MannKind's Tyvaso DPI royalties.
More positive than 18% of relationship scores this week
[mutual] MannKind acts as a junior partner to United Therapeutics regarding Tyvaso DPI.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Business Wire
6h ago
−0.6%
Price agrees with the score
$3.54 vs $3.56 close before publication (May 6) · not market-adjusted
MNKD chart →
